HSPB1 and ovarian carcinoma: First, we must address why HSP27 inhibition needs cisplatin treatment to show phenotypic differences (e.g., increased mitochondrial potential, increased mitochondrial and cellular ROS levels) in cisplatin-resistant ovarian cancer cells.